In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with direct comparisons between these two LAIs are needed.
Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study / Bartoli F.; Cavaleri D.; Callovini T.; Riboldi I.; Crocamo C.; D'Agostino A.; Martinotti G.; Bertolini F.; Ostuzzi G.; Barbui C.; Carra G.; Boschello F.; Gastaldon C.; Mazzi M.A.; Nose M.; Papola D.; Perini G.; Piccoli A.; Pievani M.; Purgato M.; Ruggeri M.; Tedeschi F.; Terlizzi S.; Turrini G.; Caroleo M.; De Fazio P.; Magliocco F.; Raffaele G.; Chirico M.; Ferrato F.; Limosani I.; Mastromo D.; Monzani E.; Ostinelli E.G.; Porcellana M.; Restaino F.; Annese P.M.; Bolognesi S.; Cerretini M.; De Capua A.; Debolini S.; Del Zanna M.; Fargnoli F.; Giannini A.; Luccarelli L.; Lucii C.; Pierantozzi E.; Tozzi F.; Bardicchia F.; Cardamone G.; Facchi E.; Magnani N.; Soscia F.; Biancosino B.; Zotos S.; Giacomin M.; Pompei F.; Spano M.; Zonta F.; Buzzi A.; Callegari C.; Calzolari R.; Caselli I.; Diurni M.; Giana E.L.; Ielmini M.; Milano A.; Poloni N.; Sani E.; Zizolfi D.; Alberini G.; Bortolaso P.; Cazzamalli S.; Costantini C.; Di Caro A.; Paronelli C.; Piantanida S.; Piccinelli M.; Alessandro P.; Barbanti S.V.; D'Ippolito C.; Gozzi M.; Moretti V.; Corbo M.; Di Capro L.; di Giannantonio M.; Fiori F.; Lorusso M.; Mancini V.; Viceconte D.; Calandra C.; Luca M.; Signorelli M.S.; Suraniti F.; Balzarro B.; Boncompagni G.; Caretto V.; Emiliani R.; Lupoli P.; Menchetti M.; Rossi E.; Storbini V.; Tarricone I.; Terzi L.; Boso M.; Catania C.; De Paoli G.; Risaro P.; Aspesi F.; Bava M.; Bono A.; Brambilla G.; Castagna G.; Lucchi S.; Nava R.; Provenzi M.; Tabacchi T.; Tremolada M.; Verrengia E.; Barchiesi M.; Oriani M.G.; Aguglia A.; Ferro M.; Ghio L.; Beneduce R.; Laffranchini L.; Magni L.R.; Rossi G.; Tura G.B.; Addeo L.; Balletta G.; De Vivo E.; Di Benedetto R.; Parise V.F.; Carpiniello B.; Pinna F.; Pecile D.; Mattei C.; Bonavigo T.; Fabrici E.P.; Panarello S.; Peresson G.; Vitucci C.; Pacetti M.; Gardellin F.; Strizzolo S.; Cossetta E.; Fizzotti C.; Moretti D.; Di Gregorio L.; Sozzi F.; Colli G.; La Barbera D.; Laurenzi S.. - In: PSYCHIATRY RESEARCH. - ISSN 0165-1781. - STAMPA. - 309:(2022), pp. 114405.1-114405.4. [10.1016/j.psychres.2022.114405]
Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study
Balzarro B.;Caretto V.;Emiliani R.;Lupoli P.;Menchetti M.Membro del Collaboration Group
;Storbini V.;Tarricone I.Membro del Collaboration Group
;Terzi L.;
2022
Abstract
In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with direct comparisons between these two LAIs are needed.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
